Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The aim of this study was to evaluate germline variant frequencies of pheochromocytoma and paraganglioma targeted susceptibility genes with next-generation sequencing method. Germline DNA from 75 cases were evaluated with targeted next-generation sequencing on an Illumina NextSeq550 instrument. , and genes were included in the study, and Sanger sequencing was used for verifying the variants. The pathogenic/likely pathogenic variants were in the , and genes, and the diagnosis rate was 24% in this study. Three different novel pathogenic variants were determined in five cases. This is the first study from Turkey, evaluating germline susceptibility genes of pheochromocytoma and paraganglioma with a detection rate of 24% and three novel variants. All patients with pheochromocytoma and paraganglioma need clinical genetic testing with expanded targeted gene panels for higher diagnosis rates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969383 | PMC |
| http://dx.doi.org/10.15586/jkcvhl.v8i1.171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Right Ventricular Paraganglioma Mimicking Coronary Artery Aneurysm: A Diagnostic Conundrum.
JACC Case Rep
September 2025
Department of Cardiovascular Disease, Wellstar Kennestone Regional Medical Center, Marietta, Georgia, USA.
Background: Paragangliomas are rare neuroendocrine tumors arising from chromaffin cells, often associated with excess catecholamine production. Cardiac paragangliomas are particularly uncommon, accounting for <1% of all cardiac tumors.
Case Summary: We report a case of a right ventricular mass that was initially misidentified as a pericardial cyst on imaging but was ultimately diagnosed as a benign paraganglioma deriving from hereditary paraganglioma and pheochromocytoma syndrome after further diagnostic evaluation and treatment.
Succinate dehydrogenase (SDH)-deficient paraganglioma and pheochromocytoma (PPGL) are rare neuroendocrine tumors for which no effective targeted therapies currently exist. To uncover new potential therapeutic targets, we performed an unbiased CRISPR-Cas9 genetic screen in immortalized mouse chromaffin cells (imCCs) with and without loss. Our screen identified genes that differentially affect cell proliferation in -deficient versus normal imCCs.
View Article and Find Full Text PDFWhen the Tumor Leaves but the Damage Lingers: A Case of Delayed Cardiomyopathy Recovery Post-Paraganglioma Resection.
J Med Cases
August 2025
Department of Cardiology, McLaren Health Care/Michigan State University, Flint, MI, USA.
Catecholamine-induced cardiomyopathy secondary to paraganglioma is a rare and potentially reversible condition. However, the course of recovery post-resection remains variable and may be delayed despite biochemical cure. We present the case of a 47-year-old male with biopsy-confirmed extra-adrenal paraganglioma who developed acute decompensated heart failure due to catecholamine-induced cardiomyopathy (left ventricular ejection fraction (LVEF) 30-35%) and multiorgan dysfunction.
View Article and Find Full Text PDFUnlabelled: Pheochromocytomas and paragangliomas (PPGLs) are rare chromaffin cell-derived neuroendocrine tumors of sympathetic (catecholamine-producing) or parasympathetic (nonsecretory) origin, frequently driven by dysregulation of hypoxia-inducible factor (HIF) signaling, particularly HIF-2α. Although often benign, PPGLs can metastasize unpredictably, with limited therapeutic options once disseminated. Progress has been hindered by the lack of robust preclinical models, especially those that capture their molecular complexity and microenvironmental influences.
View Article and Find Full Text PDFA Multicenter, Retrospective Analysis of Long-Term Survival in 255 Dogs With Pheochromocytoma Treated With Alpha-Adrenoreceptor Antagonists or Surgery (2010-2021).
J Vet Intern Med
September 2025
Clinical Science and Services, Royal Veterinary College, London, UK.
Background: The survival of dogs with pheochromocytoma (PCC) treated with adrenoreceptor antagonists has not been described or compared to surgically managed cases.
Hypothesis/objectives: The objective of this study is to evaluate the survival of medically and surgically managed dogs with PCC and investigate factors associated with survival.
Animals: Two hundred fifty-five dogs with PCC, treated with alpha-adrenoreceptor antagonists (AA) without adrenalectomy (Group 1, n = 75), adrenalectomy +/- AA (Group 2, n = 128), or neither treatment (Group 3, n = 52).